163 related articles for article (PubMed ID: 19861429)
1. Sorafenib-induced hepatic encephalopathy.
Marks AB; Gerard R; Fournier P; Coupe P; Gautier S
Ann Pharmacother; 2009 Dec; 43(12):2121. PubMed ID: 19861429
[No Abstract] [Full Text] [Related]
2. [Hepatocellular carcinoma management in the era of sorafenib].
Rosmorduc O
Gastroenterol Clin Biol; 2009 Apr; 33(4):327-33. PubMed ID: 19321281
[No Abstract] [Full Text] [Related]
3. Closing remarks.
Kudo M
Clin Drug Investig; 2012 Aug; 32 Suppl 2():52. PubMed ID: 22873627
[No Abstract] [Full Text] [Related]
4. Myositis due to Sorafenib intake in a patient with hepatocellular carcinoma.
Diaz-Sanchez A; Rodriguez-Salas N; Aramendi T; Balbin E
Dig Liver Dis; 2011 Apr; 43(4):333-4. PubMed ID: 21215716
[No Abstract] [Full Text] [Related]
5. Sorafenib: new indication. For some patients with liver cancer.
Prescrire Int; 2009 Apr; 18(100):59. PubMed ID: 19585718
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
Abou-Alfa GK; Schwartz L; Ricci S; Amadori D; Santoro A; Figer A; De Greve J; Douillard JY; Lathia C; Schwartz B; Taylor I; Moscovici M; Saltz LB
J Clin Oncol; 2006 Sep; 24(26):4293-300. PubMed ID: 16908937
[TBL] [Abstract][Full Text] [Related]
7. Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation.
Kim R; El-Gazzaz G; Tan A; Elson P; Byrne M; Chang YD; Aucejo F
Oncology; 2010; 79(1-2):62-6. PubMed ID: 21071991
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma.
Furuse J; Ishii H; Nakachi K; Suzuki E; Shimizu S; Nakajima K
Cancer Sci; 2008 Jan; 99(1):159-65. PubMed ID: 17953709
[TBL] [Abstract][Full Text] [Related]
9. [Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations].
Boige V; Barbare JC; Rosmorduc O;
Gastroenterol Clin Biol; 2008 Jan; 32(1 Pt. 1):3-7. PubMed ID: 18341970
[No Abstract] [Full Text] [Related]
10. Sorafenib-induced erythema multiforme in metastatic renal cell carcinoma.
Bilaç C; Müezzinoğlu T; Ermertcan AT; Kayhan TC; Temeltaş G; Oztürkcan S; Temiz P
Cutan Ocul Toxicol; 2009; 28(2):90-2. PubMed ID: 19514932
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib-induced acute pancreatitis.
Saadati H; Saif MW
JOP; 2010 May; 11(3):283-4. PubMed ID: 20442531
[No Abstract] [Full Text] [Related]
12. Sorafenib therapy in patients with advanced hepatocellular carcinoma in advanced liver cirrhosis.
Schütte K; Zimmermann L; Bornschein J; Csepregi A; Rühl R; Ricke J; Malfertheiner P
Digestion; 2011; 83(4):275-82. PubMed ID: 21282952
[TBL] [Abstract][Full Text] [Related]
13. Treatment of hepatocellular carcinoma with sorafenib - focus on special populations and adverse event management.
Schott E; Ebert MP; Trojan J
Z Gastroenterol; 2012 Sep; 50(9):1018-27. PubMed ID: 22965633
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib-induced palmoplantar hyperkeratosis.
Lountzis NI; Maroon MS
J Drugs Dermatol; 2008 Jun; 7(6):588-9. PubMed ID: 18561593
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.
Pinter M; Sieghart W; Graziadei I; Vogel W; Maieron A; Königsberg R; Weissmann A; Kornek G; Plank C; Peck-Radosavljevic M
Oncologist; 2009 Jan; 14(1):70-6. PubMed ID: 19144684
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
Yoon DH; Ryoo BY; Ryu MH; Lee SG; Hwang S; Suh DJ; Lee HC; Kim TW; Ahn CS; Kim KH; Moon DB; Kang YK
Jpn J Clin Oncol; 2010 Aug; 40(8):768-73. PubMed ID: 20494947
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib-induced bilateral osteonecrosis of femoral heads.
Guillet M; Walter T; Scoazec JY; Vial T; Lombard-Bohas C; Dumortier J
J Clin Oncol; 2010 Jan; 28(2):e14. PubMed ID: 19884542
[No Abstract] [Full Text] [Related]
19. Sorafenib-induced acute localized exanthematous pustulosis in a patient with hepatocellular carcinoma.
Liang CP; Yang CS; Shen JL; Chen YJ
Br J Dermatol; 2011 Aug; 165(2):443-5. PubMed ID: 21495998
[No Abstract] [Full Text] [Related]
20. Hepatic arterial thrombosis: a critical complication during combination therapy of arterial chemoinfusion and sorafenib.
Nishiofuku H; Tanaka T; Anai H; Sueyoshi S; Maeda S; Masada T; Kichikawa K
Anticancer Res; 2012 Sep; 32(9):4121-4. PubMed ID: 22993371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]